Methylprednisolone in adults hospitalized with COVID-19 pneumoniaAn open-label randomized trial (GLUCOCOVID)

被引：0

作者：

Luis Corral-Gudino

Alberto Bahamonde

Francisco Arnaiz-Revillas

Julia Gómez-Barquero

Jesica Abadía-Otero

Carmen García-Ibarbia

Víctor Mora

Ana Cerezo-Hernández

José L. Hernández

Graciela López-Muñíz

Fernando Hernández-Blanco

Jose M. Cifrián

Jose M. Olmos

Miguel Carrascosa

Luis Nieto

María Carmen Fariñas

José A. Riancho

机构：

[1] Universidad de Valladolid,Hospital Rio Hortega, Servicio de Medicina Interna

[2] Hospital Bierzo,Servicio de Medicina Interna

[3] Universidad de Cantabria,IDIVAL, Hospital U M Valdecilla, Servicio de Enfermedades Infecciosas

[4] Universidad de Valladolid,Hospital Rio Hortega, Servicio de Medicina Interna, Consulta de Enfermedades Infecciosas

[5] Universidad de Cantabria,IDIVAL, Hospital U M Valdecilla, Servicio de Medicina Interna

[6] Universidad de Cantabria,IDIVAL, Hospital U M Valdecilla, Servicio de Neumología

[7] Hospital Universitario Río Hortega,Servicio de Neumología

[8] Hospital Laredo,Servicio de Medicina Interna

[9] Hospital Sierrallana,Servicio de Medicina Interna

来源：

Wiener klinische Wochenschrift | 2021年 / 133卷

关键词：

Glucocorticoids; SARS-CoV-2; Mortality; Coronavirus Infections; Humans;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：303 / 311

页数：8

共 50 条

[21] Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial
Wang, Dongsheng
Fu, Binqing
Peng, Zhen
Yang, Dongliang
Han, Mingfeng
Li, Min
Yang, Yun
Yang, Tianjun
Sun, Liangye
Li, Wei
Shi, Wei
Yao, Xin
Ma, Yan
Xu, Fei
Wang, Xiaojing
Chen, Jun
Xia, Daqing
Sun, Yubei
Dong, Lin
Wang, Jumei
Zhu, Xiaoyu
Zhang, Min
Zhou, Yonggang
Pan, Aijun
Hu, Xiaowen
Mei, Xiaodong
Wei, Haiming
Xu, Xiaoling
FRONTIERS OF MEDICINE, 2021, 15 (03) : 486 - 494
[22] Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial
Dongsheng Wang
Binqing Fu
Zhen Peng
Dongliang Yang
Mingfeng Han
Min Li
Yun Yang
Tianjun Yang
Liangye Sun
Wei Li
Wei Shi
Xin Yao
Yan Ma
Fei Xu
Xiaojing Wang
Jun Chen
Daqing Xia
Yubei Sun
Lin Dong
Jumei Wang
Xiaoyu Zhu
Min Zhang
Yonggang Zhou
Aijun Pan
Xiaowen Hu
Xiaodong Mei
Haiming Wei
Xiaoling Xu
Frontiers of Medicine, 2021, 15 : 486 - 494
[23] Virucidal effect of povidone iodine on COVID-19 in the nasopharynx: an open-label randomized clinical trial
Arefin, Mostafa Kamal
Rumi, S. K. Nurul Fattah
Uddin, A. K. M. Nasir
Banu, Sultana Sahana
Khan, Mala
Kaiser, Ahsanul
Chowdhury, Joybaer Anam
Khan, Md Abdullah Saeed
Hasan, Mohammad Jahid
INDIAN JOURNAL OF OTOLARYNGOLOGY AND HEAD & NECK SURGERY, 2022, 74 (SUPPL 2) : 2963 - 2967
[24] Virucidal effect of povidone iodine on COVID-19 in the nasopharynx: an open-label randomized clinical trial
Mostafa Kamal Arefin
S. K. Nurul Fattah Rumi
A. K. M. Nasir Uddin
Sultana Sahana Banu
Mala Khan
Ahsanul Kaiser
Joybaer Anam Chowdhury
Md. Abdullah Saeed Khan
Mohammad Jahid Hasan
Indian Journal of Otolaryngology and Head & Neck Surgery, 2022, 74 : 2963 - 2967
[25] Open-label use of an aliphatic polyamine immunomodulator in patients hospitalized with COVID-19
Efimov, Sergey, V
Matsiyeuskaya, Natallia, V
Boytsova, Olga, V
Akhieva, Luydmila Yu
Kuntsevich, Elena, V
Troshina, Anastasia A.
Kvasova, Elena, I
Tikhonov, Anton A.
Khomyakova, Nadezhda F.
Harrison, Francisco
Rossi, Jean-Francois
Hardman, Timothy C.
DRUGS IN CONTEXT, 2022, 11
[26] Effectiveness of rosuvastatin plus colchicine, emtricitabine/tenofovir and combinations thereof in hospitalized patients with COVID-19: a pragmatic, open-label randomized trial
Gaitan-Duarte, H. G.
Alvarez-Moreno, C.
Rincon-Rodriguez, C. J.
Yomayusa-Gonzalez, N.
Cortes, J. A.
Villar, J. C.
Bravo-Ojeda, J. S.
Garcia-Pena, A.
Adarme-Jaimes, W.
Rodriguez-Romero, V. A.
Villate-Soto, S. L.
Buitrago, G.
Chacon-Sarmiento, J.
Macias-Quintero, M.
Vaca, C. P.
Gomez-Restrepo, C.
Rodriguez-Malagon, N.
ECLINICALMEDICINE, 2022, 43
[27] Colchicine and/or Naltrexone for Hospitalized COVID-19 Patients Not Requiring High Levels of Ventilatory Support (COLTREXONE): A Prospective, Randomized, Open-Label Trial
Gertner, Elie
Schullo-Feulner, Anne
Knutson, Alison
Chrenka, Ella
O'Brien, Meghan
Behrendt, Christine
Johnson, Joseph
Delaney, Daniel
CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (05)
[28] Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial
Karampitsakos, Theodoros
Papaioannou, Ourania
Tsiri, Panagiota
Katsaras, Matthaios
Katsimpris, Andreas
Kalogeropoulos, Andreas P.
Malakounidou, Elli
Zarkadi, Eirini
Tsirikos, Georgios
Georgiopoulou, Vasiliki
Sotiropoulou, Vasilina
Koulousousa, Electra
Chourpiliadi, Charikleia
Matsioulas, Apostolos
Lagadinou, Maria
Sampsonas, Fotios
Akinosoglou, Karolina
Marangos, Markos
Tzouvelekis, Argyris
CLINICAL MICROBIOLOGY AND INFECTION, 2023, 29 (03) : 372 - 378
[29] An open-label randomized controlled trial evaluating the efficacy of chloroquine/hydroxychloroquine in severe COVID-19 patients
Rea-Neto, Alvaro
Bernardelli, Rafaella Stradiotto
Dzivielevski Camara, Bruna Martins
Reese, Fernanda Baeumle
Oliveira Queiroga, Marcos Vinicius
Oliveira, Mirella Cristine
SCIENTIFIC REPORTS, 2021, 11 (01)
[30] Efficacy of Favipiravir in the Treatment of Moderate COVID-19 Patients: A Randomized, Open-label, Controlled Clinical Trial
Tehrani, Shabnam
Yadegarynia, Davood
Bagherzade, Afshin
Gachkar, Latif
Keyvanfar, Amirreza
MEDITERRANEAN JOURNAL OF INFECTION MICROBES AND ANTIMICROBIALS, 2022, 11

← 1 2 3 4 5 →